Skip to main content
. 2021 Sep;32(9):2331–2351. doi: 10.1681/ASN.2021010105

Figure 7.

Figure 7.

Effects of intensive glycemic control and losartan treatment on serum levels of AGP proteins in two clinical trials. (A) Comparison of serum EFNA4 and EPHA2 levels between subjects with standard (n=100) versus intensive glycemic control (n=100) in the ACCORD study. Standard (Std) glycemic control indicated in red; intensive (Int) glycemic control in blue. (B) Comparison of serum EFNA4 and EPHA2 levels between subjects with losartan treatment (blue bars; n=37) versus placebo (red bars; n=47) in T2D Pima cohort. Data are shown as means±SEMs adjusting for sex, duration of diabetes, systolic BP, baseline HbA1c, and GFR. *P<0.05.